{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Disease&page=21",
    "query": {
      "condition": "Retinal Disease",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 1617,
    "total_pages": 162,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Disease&page=22&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Disease&page=20&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T22:32:10.510Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02559180",
      "title": "Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetic Retinopathy",
        "Macular Edema"
      ],
      "interventions": [
        {
          "name": "aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rishi Singh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2015-10",
      "completion_date": "2020-12",
      "has_results": true,
      "last_update_posted_date": "2023-03-30",
      "last_synced_at": "2026-10-22T22:32:10.510Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02559180"
    },
    {
      "nct_id": "NCT05607810",
      "title": "Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetic Macular Edema",
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "ADVM-022",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Adverum Biotechnologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2022-08-10",
      "completion_date": "2026-04",
      "has_results": false,
      "last_update_posted_date": "2025-04-22",
      "last_synced_at": "2026-10-22T22:32:10.510Z",
      "location_count": 6,
      "location_summary": "Beverly Hills, California • Reno, Nevada • Philadelphia, Pennsylvania + 3 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Reno",
          "state": "Nevada"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Bellaire",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05607810"
    },
    {
      "nct_id": "NCT02050880",
      "title": "OCT Agreement and Crossed Precision Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glaucoma",
        "Retinal Disease",
        "Corneal Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Nidek Co. LTD.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2014-01",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-09-29",
      "last_synced_at": "2026-10-22T22:32:10.510Z",
      "location_count": 1,
      "location_summary": "Santa Ana, California",
      "locations": [
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02050880"
    },
    {
      "nct_id": "NCT00002025",
      "title": "Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cytomegalovirus Infections",
        "Cytomegalovirus Retinitis",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Ganciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Months and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-22T22:32:10.510Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002025"
    },
    {
      "nct_id": "NCT04692688",
      "title": "Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Retinopathy",
        "Diabetic Macular Edema",
        "NPDR - Non Proliferative Diabetic Retinopathy",
        "PDR - Proliferative Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "APX3330",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Opus Genetics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2021-04-08",
      "completion_date": "2023-01-25",
      "has_results": true,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-10-22T22:32:10.510Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04692688"
    },
    {
      "nct_id": "NCT02402660",
      "title": "Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stargardt Disease",
        "Stargardt Macular Degeneration",
        "Stargardt Macular Dystrophy",
        "Autosomal Recessive Stargardt Disease 1 (ABCA4-related)"
      ],
      "interventions": [
        {
          "name": "ALK-001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alkeus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "8 Years to 70 Years"
      },
      "enrollment_count": 160,
      "start_date": "2015-08",
      "completion_date": "2028-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-22T22:32:10.510Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02402660"
    },
    {
      "nct_id": "NCT03293524",
      "title": "Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leber Hereditary Optic Neuropathy"
      ],
      "interventions": [
        {
          "name": "GS010",
          "type": "GENETIC"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "GenSight Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2018-03-12",
      "completion_date": "2024-07-23",
      "has_results": true,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-10-22T22:32:10.510Z",
      "location_count": 7,
      "location_summary": "Pasadena, California • Aurora, Colorado • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03293524"
    },
    {
      "nct_id": "NCT06708624",
      "title": "Ocular Safety and Usability Study for FYB201 PFS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Age-Related Macular Degeneration",
        "Branch Retinal Vein Occlusion with Macular Edema",
        "Central Retinal Vein Occlusion with Macular Edema"
      ],
      "interventions": [
        {
          "name": "FYB201 0.5 mg (0.05 mL of 10 mg/mL)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Formycon AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2024-06-11",
      "completion_date": "2024-08-08",
      "has_results": false,
      "last_update_posted_date": "2024-11-27",
      "last_synced_at": "2026-10-22T22:32:10.510Z",
      "location_count": 4,
      "location_summary": "Campbell, California • Long Beach, California • Hagerstown, Maryland + 1 more",
      "locations": [
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Hagerstown",
          "state": "Maryland"
        },
        {
          "city": "Eugene",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06708624"
    },
    {
      "nct_id": "NCT03423823",
      "title": "Ziv-aflibercept Efficacy in Better Regulating AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Wet Macular Degeneration",
        "Wet Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ziv-Aflibercept 25 MG/ML [Zaltrap]",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kapil Kapoor",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "50 Years to 99 Years"
      },
      "enrollment_count": 62,
      "start_date": "2017-07-07",
      "completion_date": "2020-06-26",
      "has_results": false,
      "last_update_posted_date": "2020-10-06",
      "last_synced_at": "2026-10-22T22:32:10.510Z",
      "location_count": 1,
      "location_summary": "Virginia Beach, Virginia",
      "locations": [
        {
          "city": "Virginia Beach",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03423823"
    },
    {
      "nct_id": "NCT03248388",
      "title": "Argus II/ORCAM Device Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "Argus II Eyeglasses",
          "type": "DEVICE"
        },
        {
          "name": "ORCAM",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2017-08-31",
      "completion_date": "2020-10-15",
      "has_results": false,
      "last_update_posted_date": "2022-01-13",
      "last_synced_at": "2026-10-22T22:32:10.510Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03248388"
    }
  ]
}